Blood:发现新一种人类白细胞抗原基因突变导致获得性再生障碍性贫血

2017-05-30 MedSci MedSci原创

为了鉴定获得性再生障碍性贫血中自身抗原呈递中紧密相关的HLA等位基因的突变,研究人员研究了312例再生障碍性贫血患者的HLA等位基因突变频率。这一HLA等位基因的分析显示HLA-B * 40:02是最常发生突变的等位基因。在随机分析其中发生HLA-B * 40:02突变的15患者中,通过深度测序(deep sequencing)揭示了各种体细胞突变,如移码(frameshift),无义(nonse

获得性再生障碍性贫血(acquired aplastic anemia)是一种因为机体自身免疫缺陷导致的疾病。大多数研究表明获得性再生障碍性贫血归因机体自身的T细胞介导对于造血干细胞的源祖细胞(hematopoietic stem progenitor cells)的攻击。多个研究小组已经证明了,从体内分离的特定的T细胞克隆能够在体外杀死同源的造血干细胞的祖细胞。尽管已知T细胞的过免疫反应是导致这一疾病的病理,但是自身造血干细胞的哪些抗原是引起这一过免疫反应仍然不是很清楚。鉴定这些引起自身过免疫反应的抗原对于研究和治疗这一疾病是很重要的。

在最新一期的Blood杂志中,Yoshitaka Zaimoku及其同事报导了他们的发现人类白细胞抗原(human leukocyte antigen, HLA)HLA-B*40:02基因的突变与获得性再生障碍性贫血的发生有重要相关性。人类白细胞抗原HLA蛋白是负责将抗原递呈给T、B细胞引起后天免疫(adaptive immunity)的重要蛋白。但是其基因突变会导致将自身蛋白递呈给自身免疫细胞,引起过免疫反应杀死自身细胞。

为了鉴定获得性再生障碍性贫血中自身抗原呈递中紧密相关的HLA等位基因的突变,研究人员研究了312例再生障碍性贫血患者的HLA等位基因突变频率。这一HLA等位基因的分析显示HLA-B * 40:02是最常发生突变的等位基因。在随机分析其中发生HLA-B * 40:02突变的15患者中,通过深度测序(deep sequencing)揭示了各种体细胞突变,如移码(frameshift),无义(nonsense)和剪接位点(splice site mutation)突变。

这一发现进一步深化了获得性再生障碍性贫血的发病机制,发现了新的HLA基因导致异常的自身免疫反应,为将来开发对应的基因疗法提供了理论基础。

原始出处:
Yoshitaka Zaimoku et al. Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood 2017 129:2908-2916; doi: https://doi.org/10.1182/blood-2016-11-752378

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042592, encodeId=b3ac204259296, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue May 30 23:34:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623239, encodeId=56951623239a8, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Jun 01 01:34:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204402, encodeId=58f720440221, content=感谢梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Tue May 30 12:11:16 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204395, encodeId=e380204395eb, content=获得性再障的基因疗法基础性研究,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 30 10:53:01 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2042592, encodeId=b3ac204259296, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue May 30 23:34:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623239, encodeId=56951623239a8, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Jun 01 01:34:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204402, encodeId=58f720440221, content=感谢梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Tue May 30 12:11:16 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204395, encodeId=e380204395eb, content=获得性再障的基因疗法基础性研究,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 30 10:53:01 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2042592, encodeId=b3ac204259296, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue May 30 23:34:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623239, encodeId=56951623239a8, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Jun 01 01:34:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204402, encodeId=58f720440221, content=感谢梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Tue May 30 12:11:16 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204395, encodeId=e380204395eb, content=获得性再障的基因疗法基础性研究,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 30 10:53:01 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2017-05-30 jaysppr

    感谢梅斯医学!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2042592, encodeId=b3ac204259296, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue May 30 23:34:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623239, encodeId=56951623239a8, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Jun 01 01:34:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204402, encodeId=58f720440221, content=感谢梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Tue May 30 12:11:16 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204395, encodeId=e380204395eb, content=获得性再障的基因疗法基础性研究,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue May 30 10:53:01 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2017-05-30 1e0f8808m18(暂无匿称)

    获得性再障的基因疗法基础性研究,学习了。

    0